{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:11:43Z","timestamp":1789035103048,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01542-7","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:32:57Z","timestamp":1789032777000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of Hepatic Decompensation Post-Y90 Treatment in Hepatocellular Carcinoma: New Insights into Segmental TARE and Post-Treatment Dosimetry"],"prefix":"10.1007","volume":"57","author":[{"given":"Ali","family":"Afrasiabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahareh","family":"Gholami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Villalobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes L.","family":"Du Pisanie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Varela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mohnasky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Gad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Kokabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"FRCPC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"issue":"3","key":"1542_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1542_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681\u201393.","journal-title":"J Hepatol"},{"issue":"4","key":"1542_CR3","doi-asserted-by":"publisher","first-page":"e70683","DOI":"10.1002\/cam4.70683","volume":"14","author":"X Feng","year":"2025","unstructured":"Feng X, Shi ZR, Regarding. TACE Versus TARE for Patients With Hepatocellular Carcinoma: Overall and Individual Patient-Level Meta-Analysis. Cancer Med. 2025;14(4):e70683.","journal-title":"Cancer Med"},{"issue":"10","key":"1542_CR4","first-page":"807","volume":"36","author":"Y Benderli Cihan","year":"2021","unstructured":"Benderli Cihan Y, SBRT. TACE, TARE, or Combined? in the Treatment of Hepatocellular Cancer. Cancer Biother Radiopharm. 2021;36(10):807\u20138.","journal-title":"Cancer Biother Radiopharm"},{"issue":"3","key":"1542_CR5","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1002\/cam4.5125","volume":"12","author":"AM Brown","year":"2023","unstructured":"Brown AM, Kassab I, Massani M, Townsend W, Singal AG, Soydal C, et al. TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis. Cancer Med. 2023;12(3):2590\u20139.","journal-title":"Cancer Med"},{"issue":"4","key":"1542_CR6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s13139-010-0047-7","volume":"44","author":"YC Kim","year":"2010","unstructured":"Kim YC, Kim YH, Uhm SH, Seo YS, Park EK, Oh SY, et al. Radiation safety issues in y-90 microsphere selective hepatic radioembolization therapy: possible radiation exposure from the patients. Nucl Med Mol Imaging. 2010;44(4):252\u201360.","journal-title":"Nucl Med Mol Imaging"},{"issue":"8","key":"1542_CR7","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s00270-017-1704-3","volume":"40","author":"M Samim","year":"2017","unstructured":"Samim M, Lam M. Safety and Efficacy of Y-90 Radioembolization After Prior Major Hepatic Resection: Dosimetric Consideration. Cardiovasc Intervent Radiol. 2017;40(8):1293\u20134.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"7","key":"1542_CR8","doi-asserted-by":"publisher","first-page":"101434","DOI":"10.1016\/j.jhepr.2025.101434","volume":"7","author":"S Pai","year":"2025","unstructured":"Pai S, Singal AG, Hao S, Yekkaluri S, Pillai A, Moon AM, et al. The association between stage migration and overall survival after radiation-based therapies in patients with hepatocellular carcinoma. JHEP Rep. 2025;7(7):101434.","journal-title":"JHEP Rep"},{"issue":"1","key":"1542_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1055\/s-0044-1779715","volume":"41","author":"A Villalobos","year":"2024","unstructured":"Villalobos A, Pisanie JLD, Gandhi RT, Kokabi N. Yttrium-90 Radioembolization Dosimetry: Dose Considerations, Optimization, and Tips. Semin Intervent Radiol. 2024;41(1):63\u201378.","journal-title":"Semin Intervent Radiol"},{"issue":"5","key":"1542_CR10","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/hep.31819","volume":"74","author":"R Salem","year":"2021","unstructured":"Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, et al. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatology. 2021;74(5):2342\u201352.","journal-title":"Hepatology"},{"issue":"1","key":"1542_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12876-022-02204-1","volume":"22","author":"A Mahvash","year":"2022","unstructured":"Mahvash A, Chartier S, Turco M, Habib P, Griffith S, Brown S, et al. A prospective, multicenter, open-label, single-arm clinical trial design to evaluate the safety and efficacy of (90)Y resin microspheres for the treatment of unresectable HCC: the DOORwaY90 (Duration Of Objective Response with arterial Ytrrium-90) study. BMC Gastroenterol. 2022;22(1):151.","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"1542_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cpet.2025.03.002","volume":"20","author":"A Afrasiabi","year":"2025","unstructured":"Afrasiabi A, du Pisanie JL, Gholami B, Wang H, Gad S, Kokabi N. Post-Y90 PET Dosimetry. PET Clin. 2025;20(3):291\u20138.","journal-title":"PET Clin"},{"issue":"2","key":"1542_CR13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1053\/j.tvir.2019.02.011","volume":"22","author":"BB Toskich","year":"2019","unstructured":"Toskich BB, Liu DM. Y90 Radioembolization Dosimetry: Concepts for the Interventional Radiologist. Tech Vasc Interv Radiol. 2019;22(2):100\u201311.","journal-title":"Tech Vasc Interv Radiol"},{"key":"1542_CR14","doi-asserted-by":"crossref","unstructured":"Taswell CS, Studenski M, Pennix T, Stover B, Georgiou M, Venkat S et al. For Hepatocellular Carcinoma Treated with Yttrium-90 Microspheres, Dose Volumetrics on Post-Treatment Bremsstrahlung SPECT\/CT Predict Clinical Outcomes. Cancers (Basel). 2023;15(3).","DOI":"10.3390\/cancers15030645"},{"issue":"7","key":"1542_CR15","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1007\/s00270-022-03139-6","volume":"45","author":"AWP Maxwell","year":"2022","unstructured":"Maxwell AWP, Mendoza HG, Sellitti MJ, Camacho JC, Deipolyi AR, Ziv E, et al. Optimizing (90)Y Particle Density Improves Outcomes After Radioembolization. Cardiovasc Intervent Radiol. 2022;45(7):958\u201369.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"5","key":"1542_CR16","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s12325-016-0324-7","volume":"33","author":"JR Kallini","year":"2016","unstructured":"Kallini JR, Gabr A, Salem R, Lewandowski RJ. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma. Adv Ther. 2016;33(5):699\u2013714.","journal-title":"Adv Ther"},{"issue":"11","key":"1542_CR17","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1002\/hep4.2072","volume":"6","author":"M Reincke","year":"2022","unstructured":"Reincke M, Schultheiss M, Doppler M, Verloh N, Uller W, Sturm L, et al. Hepatic decompensation after transarterial radioembolization: A retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma. Hepatol Commun. 2022;6(11):3223\u201333.","journal-title":"Hepatol Commun"},{"key":"1542_CR18","doi-asserted-by":"crossref","unstructured":"Wong AWSCAHL. Predictors of Hepatic Decompensation after Yttrium90 Transarterial Radioembolization\u2014Optimizing Patient Selection. J Clin Interv Radiol ISVIR. 2024;8:83\u201389. 2024.","DOI":"10.1055\/s-0044-1786711"},{"issue":"6","key":"1542_CR19","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.jhep.2025.01.005","volume":"82","author":"R Salem","year":"2025","unstructured":"Salem R, Padia SA, Toskich BB, et al. Radiation segmentectomy for early hepatocellular carcinoma is curative. J Hepatol. 2025;82(6):1125\u201332. https:\/\/doi.org\/10.1016\/j.jhep.2025.01.005.","journal-title":"J Hepatol"},{"key":"1542_CR20","doi-asserted-by":"publisher","first-page":"103884","DOI":"10.1016\/j.eclinm.2026.103884","volume":"95","author":"B Guiu","year":"2026","unstructured":"Guiu B, Bailly C, Vibert E, PROACTIF Investigators Group, et al. Effectiveness and safety of selective internal radiation therapy using yttrium-90 glass microspheres for hepatocellular carcinoma: real-world results from the multi-center prospective PROACTIF cohort of 989 patients. EClinicalMedicine. 2026;95:103884. https:\/\/doi.org\/10.1016\/j.eclinm.2026.103884.","journal-title":"EClinicalMedicine"},{"issue":"8","key":"1542_CR21","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.2967\/jnumed.116.184713","volume":"58","author":"A Van Der Gucht","year":"2017","unstructured":"Van Der Gucht A, Jreige M, Denys A, Blanc-Durand P, Boubaker A, Pomoni A, et al. Resin Versus Glass Microspheres for (90)Y Transarterial Radioembolization: Comparing Survival in Unresectable Hepatocellular Carcinoma Using Pretreatment Partition Model Dosimetry. J Nucl Med. 2017;58(8):1334\u201340.","journal-title":"J Nucl Med"},{"issue":"7","key":"1542_CR22","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.jvir.2023.02.030","volume":"34","author":"A Villalobos","year":"2023","unstructured":"Villalobos A, Arndt L, Cheng B, Dabbous H, Loya M, Majdalany B, et al. Yttrium-90 Radiation Segmentectomy of Hepatocellular Carcinoma: A Comparative Study of the Effectiveness, Safety, and Dosimetry of Glass-Based versus Resin-Based Microspheres. J Vasc Interv Radiol. 2023;34(7):1226\u201334.","journal-title":"J Vasc Interv Radiol"},{"issue":"10","key":"1542_CR23","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1007\/s00259-022-05774-0","volume":"49","author":"M Lam","year":"2022","unstructured":"Lam M, Garin E, Maccauro M, Kappadath SC, Sze DY, Turkmen C, et al. A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging. 2022;49(10):3340\u201352.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"1542_CR24","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3348\/kjr.2025.0308","volume":"26","author":"IJ Lee","year":"2025","unstructured":"Lee IJ, Kim HC. Optimizing yttrium-90 radioembolization dosimetry for hepatocellular carcinoma: a Korean perspective. Korean J Radiol. 2025;26(7):688\u2013703. https:\/\/doi.org\/10.3348\/kjr.2025.0308.","journal-title":"Korean J Radiol"},{"key":"1542_CR25","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2147\/JHC.S294803","volume":"8","author":"C De la Garza-Ramos","year":"2021","unstructured":"De la Garza-Ramos C, Gabr A, Riaz A, et al. Biochemical safety of ablative yttrium-90 radioembolization: Percent liver treated thresholds associated with biochemical toxicity. J Hepatocell Carcinoma. 2021;8:249\u201360. https:\/\/doi.org\/10.2147\/JHC.S294803.","journal-title":"J Hepatocell Carcinoma"},{"issue":"2","key":"1542_CR26","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/hep.29107","volume":"66","author":"B Sangro","year":"2017","unstructured":"Sangro B, Mart\u00ednez-Urbistondo D, Bester L, et al. Prevention and treatment of complications of selective internal radiation therapy (radioembolization). Hepatology. 2017;66(2):654\u201367. https:\/\/doi.org\/10.1002\/hep.29107.","journal-title":"Hepatology"},{"issue":"3","key":"1542_CR27","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.21037\/jgo-22-882","volume":"14","author":"HM Lee","year":"2023","unstructured":"Lee HM, Alder L, Nguyen M, Dougherty SC, Qu Y, Thacker LR, et al. Long-term outcome analysis of Y90 radioembolization in hepatocellular carcinoma. J Gastrointest Oncol. 2023;14(3):1378\u201391.","journal-title":"J Gastrointest Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01542-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01542-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01542-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:33:01Z","timestamp":1789032781000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01542-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1542"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01542-7","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Kokabi is a consultant for SIRTeX Medical, Boston Scientific, Okami Medical, Terumo Medical, Trisalus Life SciencesDr. Villalobos is a consultant for SIRTeX Medical and Guerbett. Dr. Moon: Consultant for Intercept Pharmaceuticals, AstraZeneca, Eisai and IDEOlogy. Research funding (to institution) from DCN Diagnostics and Madrigal Pharmaceuticals.The remaining authors have no conflicts of interest to disclose. Dr. Du Pisanie is a consultant for Okami Medical.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this retrospective study, formal consent was not required. No additional informed consent was required to participate in this retrospective study.","order":2,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"216"}}